avapro has been researched along with Autoimmune Diabetes in 11 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AT-II)-receptor-antagonists have been demonstrated to cause fetotoxicity when administered to women during the second and third trimester of pregnancy." | 7.73 | Teratogenicity with angiotensin II receptor antagonists in pregnancy. ( Boix, E; Moreno, O; Picó, A; Zapater, P, 2005) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AT-II)-receptor-antagonists have been demonstrated to cause fetotoxicity when administered to women during the second and third trimester of pregnancy." | 3.73 | Teratogenicity with angiotensin II receptor antagonists in pregnancy. ( Boix, E; Moreno, O; Picó, A; Zapater, P, 2005) |
| "Previously, we have demonstrated that patients with normoalbuminuric Type 1 diabetes are characterized by impaired nitric oxide bioavailability compensated for by increased vasodilatory prostanoid-mediated vasodilation." | 2.72 | Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial. ( Allard, SE; Browne, DL; Cummings, MH; Meeking, DR; Munday, JL; Shaw, KM, 2006) |
| "Irbesartan and creatinine clearance in NIDDM patients." | 2.40 | Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system. ( Hollenberg, NK, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Jacobsen, P | 2 |
| Andersen, S | 2 |
| Rossing, K | 2 |
| Jensen, BR | 1 |
| Parving, HH | 2 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| Chiarelli, F | 1 |
| Di Marzio, D | 1 |
| Santilli, F | 1 |
| Mohn, A | 1 |
| Blasetti, A | 1 |
| Cipollone, F | 1 |
| Mezzetti, A | 1 |
| Verrotti, A | 1 |
| Salcedo-Alejos, M | 1 |
| Banda-Espinoza, F | 1 |
| Rodríguez-Morán, M | 1 |
| Guerrero-Romero, F | 1 |
| Browne, DL | 1 |
| Meeking, DR | 1 |
| Allard, SE | 1 |
| Munday, JL | 1 |
| Shaw, KM | 1 |
| Cummings, MH | 1 |
| Boix, E | 1 |
| Zapater, P | 1 |
| Picó, A | 1 |
| Moreno, O | 1 |
| Wong, DW | 1 |
| Oudit, GY | 1 |
| Reich, H | 1 |
| Kassiri, Z | 1 |
| Zhou, J | 1 |
| Liu, QC | 1 |
| Backx, PH | 1 |
| Penninger, JM | 1 |
| Herzenberg, AM | 1 |
| Scholey, JW | 1 |
| Hollenberg, NK | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Hansen, BV | 1 |
4 reviews available for avapro and Autoimmune Diabetes
| Article | Year |
|---|---|
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1997 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
5 trials available for avapro and Autoimmune Diabetes
| Article | Year |
|---|---|
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Comp | 2003 |
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.
Topics: Adolescent; Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Case-Co | 2005 |
Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Child; Creatinine; Diabetes | 2005 |
Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial.
Topics: Acetylcholine; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; C | 2006 |
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2002 |
2 other studies available for avapro and Autoimmune Diabetes
| Article | Year |
|---|---|
Teratogenicity with angiotensin II receptor antagonists in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Bipheny | 2005 |
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.
Topics: Actins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Anima | 2007 |